Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
See also
Décision d'accès précoce
16/11/2022
eNrdWNty2jAQfc9XMH6XzbWYjiHT0qRlJplSEqadvjBCXoOokBxdgPTrK2PSko7dNCJ+yQtjdNldSeecXSk6361ZbQNSUcH7XsOvezXgRMSUL/re9PYShd754Cxa4Q0+Gtb1636j6dUIw0r1vazXnwPmyv92ffUB7HyQ3uCsFon5Coh+NM5oyvxPWC2vcZqNqUUbQePaGvRSxH0vNXrfWouUljaKwVbIHyrFBKLg0HLcu5q1j9ujIDP2H1aNAnmF+aLQKHAnm8RICVwPsYaFkPeFplMZN2bNXvim0QudnFA1ASWMJDDGejmWYkNjiAt9JZgpcHKSbOMbkBsGOnNSaDxYkbVyMo5XeDeBu1Fx0O9s71DvNKqjRrfba3e7nUa71eo5uZJHW1UMH7uIIJ21WmEnDNsB8CAGQjOUI46a9WYT1VvdThCTQMEaxQY16oiLDaznEvJ+20YEY7AAFANiGC2x0YDsj5BU7xsV5vYjFVLbDyQhMQrFCBMCCqXSsoU8zFWp9Y7Zfp5J6c6iyREk48wbqwgeVA0fQ70iPxLunoRhTFXK8L2/UqnrVmGJbTdIK0jVLSRbwa20Esnsnv1lnxvGgmdGPT0IWEURZ/o4FIbrEh27nLhuxFBYNuzKT9RNevXugEUK6uXM/hS8OO2MzZxR4qqtVv0MKD2djMql9VWq0nusYCqrk6WvlMdiq15e7o7hVVH0+5NgTxQNnY4zm79bLJfk3AsjRQqBFUKqTtG3EU/Eqcpm6VFs6oEcr48X+1pUEMygpBpFjmprCfFQPFdGueronHcUGv14ceuK0y8G5P3N/m+haRr3fyPMLRVVkd8sK0oDfz7Hcqn55z0lIbNm2G2HLbdbipHFSrbUOlVvg2C73fpLrHKy+Yl8vSnvqNyp7rJWSU2V15h52qgo9HleDzwPKq7Mf6rqOvUmcZh/uLEU+tDSwAlnkSeJyqR8dPHy2eHPNaKysMeP1Kw6N/uSH2srSVVVgGZeXP6dlI/sufJLaQXic5LQkle0UlxGQf6CNziLguz1bnD2CxKbqBE=
78ysv6Q7DxZ6ABf1